Research on CJC-1295 no DAC Peptide?
Increased GH and IGF-1 Levels: Mod GRF 1-29 transiently stimulates growth hormone production by targeting the pituitary gland, leading to pulsatile increases in GH levels and secondary rises in IGF-1 (1). Clinical trials, including studies on GHRH gene ablation and human consumption, demonstrated dose-dependent, sustained IGF-1 elevation with preserved growth hormone synthesis. These findings highlight its potential for supporting muscle strength, maintaining normal body weight, and optimizing peptide hormone function (2).
Improved Body Composition and Weight Loss: This peptide boosts natural growth hormone and increases IGF-1 levels. This pulsatile release helps build muscle, maintain lean body mass, and reduce fat (3).
Studies on animals, specifically GHRH-knockout mice, showed better body composition, including more lean tissue and less fat, after treatment (4). More frequent dosing can even enhance these results. While human data is still limited, evidence suggests that increasing GH-IGF-1 activity can improve muscle mass and decrease both visceral and subcutaneous fat.
Better Sleep: Research suggests that modified GRF enhances GH and IGF-1 levels, which are linked to sleep regulation. Studies show that GH deficiency is associated with increased slow-wave sleep (SWS) intensity, likely due to overactive hypothalamic GHRH.
GH replacement therapy, including agents like CJC-1295, can normalize this by reducing excessive SWS intensity and improving sleep patterns. CJC-1295’s sustained GH release may support better sleep regulation, though its direct effects on sleep require further study (5).
Enhanced Cognitive Function: Research has shown that CJC-1295 without DAC may support cognitive function by enhancing growth hormone (GH) and IGF-1 levels, which are critical for brain health. Studies show that GHRH administration improves executive function and verbal memory in both healthy older adults and those with mild cognitive impairment (MCI) (6).
Additionally, GH has neuroprotective effects, promoting recovery in stroke models by aiding spatial memory and neuronal repair. These findings suggest CJC-1295’s potential to enhance cognitive performance and support brain health during aging and neurodegenerative conditions (7).
Cardioprotective: Research has shown that GRF 1-29 exhibits cardioprotective properties by activating cardiac repair mechanisms independent of the GH/IGF-1 axis. Studies show GHRH agonists like JI-38 improve cardiac function, reduce remodelling, and enhance anti-apoptotic gene expression after myocardial infarction (MI) (8).
Unlike IGF-1, which modulates inflammation and promotes anti-inflammatory macrophages, GHRH agonists directly stimulate cardiac precursor cell proliferation and repair, offering a promising therapeutic pathway for heart injury recovery (9).
Wound Healing and Tissue Repair: Research indicates that CJC-1295 no DAC supports wound healing and tissue repair by stimulating growth hormone (GH) release, which enhances IGF-1 production. IGF-1 promotes keratinocyte migration, wound epithelialization, and hyaluronan synthesis, aiding in challenging wound recovery, such as burns and diabetic ulcers (10).
Additionally, GH improves collagen deposition, angiogenesis, and granulation tissue formation while reducing inflammation, as seen in intestinal healing models. These combined effects highlight its potential in accelerating tissue repair (11).
Buy CJC-1295 no DAC Pre-Mixed Pen for in vitro testing and laboratory experimentation. There is the option to buy individual cartridges or a pen kit, which includes an injection pen, single use pen needle tips, and a single cartridge containing CJC-1295 no DAC pre-mixed with bacteriostatic water.
References
(1) Ionescu M, Frohman LA (2006) Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog – J Clin Endocrinol Metab. 2006 Dec, Volume 91 (Issue 12), Pages 4792-7.
(2) Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar, Volume 91, Issue 3, 1 Pages 799-805.
(3) L Sackmann-Sala, J Ding, L A Frohman, and J J Kopchick (2009) Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects – Growth Hormone & IGF Research, 2009 Dec, Volume 19 (Issue 6), Pages 471-7.
(4) M Alba, D Fintini, A Sagazio, B Lawrence, et al (2006) Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse – American Journal of Physiology, Endocrinology & Metabolism, 2006 Dec, Volume 291 (Issue 6), Pages E1290-4.
(5) L L Morselli, A Nedeltcheva, R Leproult, et al (2013) Impact of growth hormone replacement therapy on sleep in adult patients with growth hormone deficiency of pituitary origin – European Journal of Endocrinology, 2013 Apr 15, Volume 168 (Issue 5), Pages 10.1530/EJE-12-1037.
(6) L D Baker, S M Barsness, S Borson, et al (2012) Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults – Arch Neurol, 2012 Nov, Volume 69 (Issue 11), Pages 1420–1429.
(7) Gohil A, Eugster E. Growth Hormone Deficiency and Excessive Sleepiness: A Case Report and Review of the Literature. Pediatr Endocrinol Rev. 2019, Volume 17, Issue 1, 1 December 2009, Pages 41-46.
(8) R M Kanashiro-Takeuchi, K Tziomalos, L M Takeuchi, et al (2010) Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction – Proc Natl Acad Sci U S A, 2010 Jan 21, Volume 107 (Issue 6), Pages 2604–2609.
(9) A Heinen, R Nederlof, P Panjwani, et al (2018) IGF1 Treatment Improves Cardiac Remodeling after Infarction by Targeting Myeloid Cells – Molecular Therapy, 2018 Nov 1, Volume 27 (Issue 1), Pages 46–58.
(10) Z Garoufalia, A Papadopetraki, E Karatza, et al (2021) Insulin-like growth factor-I and wound healing, a potential answer to non-healing wounds: A systematic review of the literature and future perspectives – Biomedical Reports, 2021 Jun 8, Volume 15 (Issue 2), Page 66.
(11) M A Küper, S Trütschel, J Weinreich, et al (2016) Growth hormone abolishes the negative effects of everolimus on intestinal wound healing – World Journal Gastroenterology, 2016 May 7, Volume 22 (Issue 17), Pages 4321–4329.